Patent intelligence · Companies
Company patent strength
Non-educational filers ranked by their patent portfolio. Grant rate and lapsed share expose where high filing volume is not matched by granted patents. Domestic filers lead — toggle to foreign applicants to see who is entering the Indian market.
Free to browse the ranking. Sign into open a filer's full profile — inventors, filing trend and quality index. See how we rank.
Why this page exists — and how to read it
Filing volume and IP quality are different things. This leaderboard ranks non-educational filers by portfolio, but the grant-rate and lapsed sorts are where the judgement lives: they separate companies whose filings survive examination from those accumulating paper.
- Investors
- High grant rate on steady filing usually means a real R&D engine; big volume with a high lapsed share is a red flag worth asking about.
- Founders & operators
- These are the incumbents and potential acquirers in your space — open a filer to see the walls you'd build against.
- Corporate & R&D
- Benchmark competitors' portfolios and grant rates; toggle to foreign to watch who is entering the Indian market.
💬 The grant-rate sort applies a 20-filing floor so tiny portfolios can't top the list.
3,207 foreign filers with 5+ patents · page 35
| # | Filer | Patents↓ | Granted↓ | Lapsed↓ | Pending↓ | Active |
|---|---|---|---|---|---|---|
| 1701 | ALKERMES PHARMA IRELAND | 8 | 00% | 1 | 7 | 2022–2022 |
| 1702 | ALLSTATE INSURANCE | 8 | 225% | 3 | 3 | 2019–2026 |
| 1703 | ALPINESTARS RESEARCH | 8 | 00% | 0 | 8 | 2022–2025 |
| 1704 | ALTERYX | 8 | 450% | 0 | 4 | 2023–2025 |
| 1705 | ALTRIS | 8 | 112.5% | 0 | 7 | 2022–2026 |
| 1706 | ANALOG POWER CONVERSION | 8 | 112.5% | 4 | 3 | 2022–2024 |
| 1707 | APR | 8 | 00% | 0 | 8 | 2025–2025 |
| 1708 | ARCTURUS THERAPEUTICS | 8 | 00% | 0 | 8 | 2022–2025 |
| 1709 | ARRIVER SOFTWARE | 8 | 00% | 1 | 7 | 2022–2025 |
| 1710 | ARSENAL BIOSCIENCES | 8 | 00% | 1 | 7 | 2023–2026 |
| 1711 | ARTECO | 8 | 225% | 0 | 6 | 2022–2026 |
| 1712 | ASAKA RIKEN | 8 | 112.5% | 1 | 6 | 2023–2026 |
| 1713 | ASSEMBLY BIOSCIENCES | 8 | 00% | 1 | 7 | 2022–2026 |
| 1714 | AT S AUSTRIA TECHNOLOGIE SYSTEMTECHNIK AKTIENGESELLSCHAFT | 8 | 00% | 0 | 8 | 2025–2025 |
| 1715 | ATLAS COPCO WUXI COMPRESSOR | 8 | 112.5% | 1 | 6 | 2022–2025 |
| 1716 | AULTON NEW ENERGY AUTOMOBILE TECHNOLOGY | 8 | 00% | 0 | 8 | 2024–2025 |
| 1717 | AVL LIST | 8 | 112.5% | 1 | 6 | 2022–2026 |
| 1718 | BAE SYSTEMS CONTROLS | 8 | 112.5% | 0 | 7 | 2022–2026 |
| 1719 | BAUER MASCHINEN | 8 | 00% | 0 | 8 | 2023–2026 |
| 1720 | BAVARIAN NORDIC A S | 8 | 00% | 0 | 8 | 2022–2025 |
| 1721 | BELVAC PRODUCTION MACHINERY | 8 | 00% | 0 | 8 | 2023–2026 |
| 1722 | BIOATLA | 8 | 00% | 0 | 8 | 2022–2025 |
| 1723 | BLUE PRISM | 8 | 00% | 0 | 8 | 2022–2025 |
| 1724 | BOEGLI GRAVURES | 8 | 00% | 1 | 7 | 2023–2025 |
| 1725 | BOOMCLOUD 360 | 8 | 787.5% | 0 | 1 | 2021–2026 |
| 1726 | BOSCH AUTOMOTIVE PRODUCTS SUZHOU | 8 | 00% | 0 | 8 | 2022–2026 |
| 1727 | BRAY INTERNATIONAL | 8 | 00% | 0 | 8 | 2022–2026 |
| 1728 | CALB TECHNOLOGY | 8 | 00% | 1 | 7 | 2022–2022 |
| 1729 | CARIBOU BIOSCIENCES | 8 | 00% | 0 | 8 | 2023–2025 |
| 1730 | CASCADE | 8 | 112.5% | 0 | 7 | 2022–2025 |
| 1731 | CC BIOTECHNOLOGY | 8 | 225% | 0 | 6 | 2022–2025 |
| 1732 | CHEMIMAGE | 8 | 00% | 8 | 0 | 2022–2022 |
| 1733 | CHONGQING HAIER AIR CONDITIONER | 8 | 562.5% | 0 | 3 | 2023–2023 |
| 1734 | CHR HANSEN HMO | 8 | 112.5% | 0 | 7 | 2022–2023 |
| 1735 | CLARA FOODS | 8 | 00% | 2 | 6 | 2022–2024 |
| 1736 | CLARIANT PRODUKTE DEUTSCHLAND | 8 | 112.5% | 6 | 1 | 2022–2025 |
| 1737 | CLAROS TECHNOLOGIES | 8 | 00% | 0 | 8 | 2024–2026 |
| 1738 | CONVIDA WIRELESS | 8 | 00% | 0 | 8 | 2022–2025 |
| 1739 | CUREVAC SE | 8 | 00% | 0 | 8 | 2022–2025 |
| 1740 | DART INDUSTRIES | 8 | 00% | 0 | 8 | 2022–2024 |
| 1741 | DECATHLON | 8 | 00% | 0 | 8 | 2023–2026 |
| 1742 | DELTA GALIL INDUSTRIES | 8 | 00% | 0 | 8 | 2023–2025 |
| 1743 | DENTSU | 8 | 112.5% | 0 | 7 | 2018–2026 |
| 1744 | DIZAL JIANGSU PHARMACEUTICAL | 8 | 00% | 0 | 8 | 2022–2025 |
| 1745 | DONGGUAN NVT TECHNOLOGY | 8 | 337.5% | 1 | 4 | 2022–2025 |
| 1746 | DRAGONFLY THERAPEUTICS | 8 | 00% | 1 | 7 | 2022–2025 |
| 1747 | DRUVA | 8 | 00% | 0 | 8 | 2022–2024 |
| 1748 | DSPACE | 8 | 00% | 0 | 8 | 2022–2025 |
| 1749 | E THERAPEUTICS | 8 | 00% | 0 | 8 | 2023–2025 |
| 1750 | EGUN | 8 | 112.5% | 0 | 7 | 2023–2024 |
Educational institutes are excluded — see the institute leaderboard. Attribution is by patent assignee record; a jointly-owned patent is credited to each co-owner, so a co-filed patent counts for every company on it. "Lapsed" = abandoned, withdrawn, deemed-withdrawn or refused; "Pending" = awaiting examination or in prosecution. Want to filter by technology or value category? Browse the filer explorer →
Rankings use patent-registry status (grant rate, examination, claim depth) as a quality proxy — directional, not advice; see methodology. Read the ranking methodology →